Privia Health (PRVA) Q4 2025 earnings review
Profitability Surges on Model Resilience, But 2026 Volume Growth Decelerates
Privia Health closed 2025 by beating the high end of all guidance metrics, highlighted by a 38.8% full-year surge in Adjusted EBITDA and massive free cash flow generation ($163.4M). Q4 Revenue climbed 17.4% YoY to $541.2M, driven by strong fee-for-service performance and the strategic integration of recent M&A (Evolent ACO and IMS). However, while the bottom-line growth is Accelerating, 2026 guidance indicates Decelerating top-line and volume metrics. Attributed lives are projected to grow just ~2.2% at the midpoint, reflecting management's cautious stance on Medicare Advantage and a disciplined avoidance of unfavorable full-risk capitation contracts.
🐂 Bull Case
Privia generated $163.4M in operating cash flow in FY25 (a 130% conversion rate from Adjusted EBITDA) and sits on $479.7M in cash with zero debt, providing massive flexibility for accretive M&A without dilution.
Full-year Adjusted EBITDA grew 38.8%, significantly outpacing the 22.3% revenue growth, proving the scalability of Privia's tech-enabled fee-for-service and shared-risk platform.
🐻 Bear Case
After growing Attributed Lives by 22.7% in 2025 (aided by acquisitions), 2026 guidance implies a meager 0.6% to 3.8% growth rate, signaling a potential plateau in organic value-based care expansion.
Provider expenses are rising faster than revenue. In Q4, Provider Expense jumped 20.2% YoY, throttling Gross Profit growth to just 7.4%.
⚖️ Verdict: 🟢
Bullish. Privia's deliberate choice to sacrifice unprofitable top-line growth (by avoiding risky Medicare Advantage capitation) in favor of highly profitable, shared-risk and FFS models is paying off. The resulting cash hoard and structural margin expansion outweigh the optical deceleration in 2026 patient volume.
Key Themes
Disciplined M&A as a Strategic Catalyst
Management's deployment of capital is a primary growth engine. The 2025 acquisitions of IMS in Arizona ($95M) and Evolent Health's ACO business ($100M+) successfully closed and immediately contributed to the year-end beat. These deals brought in over 148,000 combined value-based lives and expanded operations into six new states, providing a robust integration runway to cross-sell Privia's full tech platform in 2026.
Provider Expense Squeezing Gross Margins
While overall profitability metrics look fantastic, there is a structural squeeze at the gross margin level. Q4 Total Revenue grew 17.4% YoY, but Provider Expense surged 20.2% to $424.6M. Consequently, Q4 Gross Profit grew a lackluster 7.4%, resulting in gross margin dropping from 23.0% in Q4 2024 to 21.0% in Q4 2025.
Avoidance of Full-Risk Capitation
Privia is actively avoiding the Medicare Advantage (MA) full-risk capitation trap that has severely damaged competitors. While Capitated Revenue grew 44.8% to $308.4M in FY25, management previously stressed they will not expand this book unless economics are highly favorable. This strategic caution protects the bottom line but directly contributes to the Decelerating top-line and lives guidance for 2026.
Stellar Operating Leverage
Privia's 'Platform Contribution' and scalable tech model are working as designed. For FY25, Care Margin grew 14.4%, Platform Contribution grew 20.0%, and Adjusted EBITDA surged 38.8%. As fixed costs (General and Administrative grew only 9.5% in FY25) are spread over a larger revenue base, incremental margins drop efficiently to the bottom line.
Other KPIs
Accelerating. FCF jumped 49.6% YoY from $109.3M in 2024. This represents an incredible 130% conversion rate of Adjusted EBITDA into free cash flow. This was achieved with essentially zero capital expenditures, showcasing the highly capital-light nature of Privia's tech and services platform.
Stable. Up 12.3% YoY from 4,789 in 2024. Privia successfully beat its recently raised full-year target of 5,300-5,350 providers. Organic provider growth remains the foundational driver for predictable fee-for-service revenue, and guidance points to ~10.6% growth next year.
Decelerating. While up 9.6% YoY, Q4 collections represented a sequential drop from Q3's $940.4M. This highlights the typical seasonality tied to Q3 shared savings true-ups, but the single-digit YoY growth pace validates the tighter 2026 guidance.
Guidance
Decelerating. Implies 19.5% YoY growth at the midpoint ($150M), down from the 38.8% growth achieved in 2025. Still, achieving ~20% EBITDA growth entirely organically (guidance assumes no new M&A) demonstrates robust core profitability.
Decelerating violently. Implies only 0.6% to 3.8% YoY growth, compared to the 22.7% growth seen in 2025. This suggests minimal organic expansion in risk arrangements or expected churn from unfavorable payer contracts.
Decelerating. The midpoint of $2.4B implies 13.1% YoY growth, a step down from the 22.3% growth recorded in 2025. Given that provider counts are guided up ~10.6%, revenue per provider growth is expected to moderate.
Decelerating from the ~130% achieved in 2025. Management previously indicated this expected normalization is due to the company exhausting its net operating loss (NOL) carryforwards and transitioning into a full cash taxpayer.
Key Questions
Gross Margin Dynamics
Q4 saw Provider Expense grow considerably faster than Revenue, causing gross margin compression. How much of this is structural due to new provider contract structures versus temporary integration noise from the Evolent and IMS deals?
The Stalling Lives Pipeline
FY26 guidance implies virtually flat Attributed Lives growth (up ~2% at the midpoint). Is this purely a defensive measure to avoid bad MA risk, or are you seeing elevated churn/competition for primary care panels in your existing markets?
Capital Allocation Tipping Point
You will exit 2026 with an estimated $600M in cash and zero debt. With guidance explicitly assuming zero new M&A, at what point does the lack of capital deployment become a drag on ROE, and when does a structural buyback program become priority one?